SU2C establishes $3.25M head and neck cancer research team

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Stand Up To Cancer announced the Stand Up To Cancer–Fanconi Anemia Research Fund–Farrah Fawcett Foundation Head and Neck Cancer Research Team, which will focus on new approaches to address head and neck squamous cell carcinoma, with an emphasis on cancers related to the human papillomavirus and Fanconi anemia.

The team has been awarded $3.25 million over three years to advance therapies, support new approaches, and improve patient outcomes for head and neck cancers. The team will receive $1.5 million each from the Fanconi Anemia Research Fund and the Farrah Fawcett Foundation. The American Head and Neck Society and the Head and Neck Cancer Alliance also each provided $125,000 in support. 

Agata Smogorzewska, associate professor at The Rockefeller University, will lead the research team and Barbara Burtness, professor of medicine, interim associate director for diversity, equity and inclusion and co-leader, Developmental Therapeutics Program at Yale Cancer Center and Smilow Cancer Hospital, will serve as co-leader.

Table of Contents

YOU MAY BE INTERESTED IN

The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk. 
With artificial intelligence becoming an increasingly ubiquitous part of the fabric of modern life, Cancer Grand Challenges has committed $10 million to a project aimed at developing AI “co-scientists”—AI agents that could help cancer researchers analyze data, generate hypotheses, and suggest new experiments.
For decades, cancer treatment has largely followed a familiar model: Identify the disease, determine its stage, and select the therapy most likely to benefit patients with similar characteristics. Even as targeted therapies and immunotherapies have transformed oncology, we have generally developed drugs for populations rather than individuals.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login